Applied Health Economics and Health Policy最新文献

筛选
英文 中文
Speed over Value: Korea's Recent Overhaul in Pharmaceutical Pricing and Reimbursement. 速度高于价值:韩国最近在药品定价和报销方面的改革。
IF 3.1 4区 医学
Applied Health Economics and Health Policy Pub Date : 2026-10-03 DOI: 10.1007/s40258-026-01078-8
Hye-Young Kwon
{"title":"Speed over Value: Korea's Recent Overhaul in Pharmaceutical Pricing and Reimbursement.","authors":"Hye-Young Kwon","doi":"10.1007/s40258-026-01078-8","DOIUrl":"https://doi.org/10.1007/s40258-026-01078-8","url":null,"abstract":"<p><p>Since 2007, South Korea has been a leading country in Asia in health technology assessment (HTA). In March 2026, a 100-day listing pathway using international reference pricing (IRP) without pre-reimbursement HTA was introduced for rare disease drugs, with plans to expand to all new drugs. This policy represents a fundamental shift from ex-ante to ex-post value assessment, de-prioritizing the cost-effectiveness analysis framework established in 2007. Given the lessons from IRP, the global movement toward value-based pricing, and Korea's current financial challenges, it is essential to develop a system that leverages the accumulated knowledge on HTA over the past two decades to balance expedited access with rigorous value assessment. Therefore, further specified post-evaluation mechanisms incorporating value for money principles are needed to avoid undermining value assessment and diverging from the global trend toward strengthening value-based healthcare.</p>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Early Value Assessment of Biomarker-Guided Precision Medicine for Treatment-Resistant Hypertension: A Headroom and Threshold Analysis 生物标志物引导的精准医学对难治性高血压的早期价值评估:阈值分析。
IF 3.1 4区 医学
Applied Health Economics and Health Policy Pub Date : 2026-09-30 DOI: 10.1007/s40258-026-01075-x
Teebah Abu-Zahra, Sabine Grimm, Mirre Scholte, Ana I. Casas, Peter Saliba-Gustafsson, Paolo Parini, Manuela Joore
{"title":"An Early Value Assessment of Biomarker-Guided Precision Medicine for Treatment-Resistant Hypertension: A Headroom and Threshold Analysis","authors":"Teebah Abu-Zahra,&nbsp;Sabine Grimm,&nbsp;Mirre Scholte,&nbsp;Ana I. Casas,&nbsp;Peter Saliba-Gustafsson,&nbsp;Paolo Parini,&nbsp;Manuela Joore","doi":"10.1007/s40258-026-01075-x","DOIUrl":"10.1007/s40258-026-01075-x","url":null,"abstract":"<div><h3>Background</h3><p>Treatment-resistant hypertension (TRH), defined as uncontrolled blood pressure despite the use of three or more antihypertensive drugs or requiring four or more drugs for control, affects 10.3% of patients with hypertension and increases cardiovascular risk. Biomarker-guided precision treatments have the potential to address unmet needs in TRH. This health economic modelling study assessed the headroom (that is the maximum potential value of a hypothetical biomarker-guided treatment strategy with zero treatment costs and 100% effectiveness) in the TRH population in general, then in a specific subgroup with elevated levels of NADPH oxidase 5 (NOX5-positive).</p><h3>Methods</h3><p>A decision tree and a state transition model were developed to estimate headroom in patients with TRH and in the NOX5-positive subgroup (assumed to comprise 25% of the population). The model adopted a Dutch healthcare perspective over a lifetime horizon, estimating costs and quality-adjusted life years (QALYs), with a net monetary benefit threshold of €20,000 per QALY. Uncertainty was explored through sensitivity, scenario and threshold analyses.</p><h3>Results</h3><p>The room for improvement in TRH patients includes 2.94 additional life years, 3.45 QALYs, and €23,292 cost savings per patient. Successfully diagnosing and treating NOX5-positive patients could yield a gain of 0.53 life years and 0.63 QALYs, with cost savings of €4835 per patient. The biomarker-guided treatment remained cost effective even at annual costs of €5045 per patient or if only two of 1000 patients were NOX5-positive and successfully treated.</p><h3>Conclusion</h3><p>Patients with TRH have room for improvement in life expectancy, quality of life, and cardiovascular outcomes with a biomarker-guided treatment strategy. These findings support further research and development of targeted treatments to address this unmet medical need.</p><h3>Graphical abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":"24 6","pages":"1093 - 1108"},"PeriodicalIF":3.1,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40258-026-01075-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Practical Framework for Understanding Cost-Effectiveness and Decision Risk in Health Benefits Package Design 健康福利包设计中理解成本效益和决策风险的实用框架。
IF 3.1 4区 医学
Applied Health Economics and Health Policy Pub Date : 2026-09-30 DOI: 10.1007/s40258-026-01072-0
Cassandra Nemzoff, Sabine Grimm, Manuela Joore, Andres Madriz-Montero, Stella Matutina Umuhoza, James Humuza, Sedona Sweeney, Rob Baltussen, Anna Vassall
{"title":"A Practical Framework for Understanding Cost-Effectiveness and Decision Risk in Health Benefits Package Design","authors":"Cassandra Nemzoff,&nbsp;Sabine Grimm,&nbsp;Manuela Joore,&nbsp;Andres Madriz-Montero,&nbsp;Stella Matutina Umuhoza,&nbsp;James Humuza,&nbsp;Sedona Sweeney,&nbsp;Rob Baltussen,&nbsp;Anna Vassall","doi":"10.1007/s40258-026-01072-0","DOIUrl":"10.1007/s40258-026-01072-0","url":null,"abstract":"<div><h3>Background</h3><p>Global cost-effectiveness evidence is often used in health benefits package (HBP) assessments but is uncertain and subject to the risk of making the wrong decision. HBP assessments use ‘adaptive’ health technology assessment (aHTA) methods, including reviews of existing cost effectiveness studies and eliciting expert opinion to expedite cost-effectiveness evaluations due to substantial time and data constraints. Using aHTA methods poses a risk of making the wrong decision. However, existing methods for assessing risk, such as value of information analysis (VOI), are time- and data-intensive.</p><h3>Objectives</h3><p>Our objectives were to develop a practical method to evaluate the risk of making the wrong decision in HBP design and to test this approach in Rwanda.</p><h3>Methods</h3><p>We developed a heuristic framework to help decision makers determine whether aHTA methods are sufficient for decision making or de novo cost-effectiveness modelling might be needed. The framework was created by adapting the ‘Appraisal of Risk Chart’ (ARCH), which was originally designed to evaluate the risk of decision making from de novo cost-effectiveness analyses. We tested the adapted ARCH using an assessment of 136 cancer interventions in Rwanda, where each intervention was charted on the ARCH according to its risk profile.</p><h3>Results</h3><p>In Rwanda, 41 cancer interventions were considered low risk on the ARCH and the remainder were uncertain.</p><h3>Conclusions</h3><p>We demonstrate that it is feasible to use the ARCH to determine whether aHTA methods are sufficient or more research is needed in HBP assessments.</p></div>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":"24 6","pages":"1081 - 1091"},"PeriodicalIF":3.1,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40258-026-01072-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spillover Effects of Medical Innovations: A Universal and Scalable Approach to Measure the Societal Value of Avoided Informal Care Time 医疗创新的溢出效应:一种普遍和可扩展的方法来衡量避免非正式护理时间的社会价值。
IF 3.1 4区 医学
Applied Health Economics and Health Policy Pub Date : 2026-09-18 DOI: 10.1007/s40258-026-01068-w
Rebecca Grün, Diego Hernandez, Adnan Atitallah, Platon Peristeris, Lena Steinbeck, Eva Levi,, Malina Müller
{"title":"Spillover Effects of Medical Innovations: A Universal and Scalable Approach to Measure the Societal Value of Avoided Informal Care Time","authors":"Rebecca Grün,&nbsp;Diego Hernandez,&nbsp;Adnan Atitallah,&nbsp;Platon Peristeris,&nbsp;Lena Steinbeck,&nbsp;Eva Levi,,&nbsp;Malina Müller","doi":"10.1007/s40258-026-01068-w","DOIUrl":"10.1007/s40258-026-01068-w","url":null,"abstract":"<div><h3>Background and Objective</h3><p>Informal caregiving is essential to comprehensive patient care, yet sustained caregiving can lower caregivers’ quality of life and productivity, with implications for labor supply and economic growth. Most studies quantify caregiver burden without linking it to patients’ utility, obscuring how health gains translate into caregiving demand. We extend a published framework for valuing the social impact of medical interventions by incorporating informal caregiving as a scalable dimension of societal value, enabling estimation of caregiver productivity effects where direct caregiver data are unavailable.</p><h3>Methods</h3><p>We established a generic relationship between patients’ quality-adjusted life-years (QALYs) and caregiving time by leveraging published correlations between EQ-5D and daily care time. Incremental QALYs were converted into age- and ICD10 chapter-specific hourly reductions in caregiving time. To address the “QALY-trap,” we established a QALY-composition approximation. Using nationally representative time-use data, we estimated how freed time is reallocated to paid work, unpaid work, and leisure, and we quantified the socioeconomic value of avoided informal care time as opportunity costs, including direct effects on paid and unpaid work and broader impacts.</p><h3>Results</h3><p>We demonstrated use in a case study of relapsing-remitting multiple sclerosis treated with ofatumumab across five countries. Ofatumumab reduced informal caregiving between 17.34 and 18.38 h per treated patient-year. In Germany, caregiver productivity gains were $468 per patient-year and represented about 7.2% of the patient productivity component of total social impact. Findings were directionally similar across settings.</p><h3>Conclusions</h3><p>The method incorporates the caregiver perspective into economic evaluations by linking patient utility gains to changes in caregiving demand and their societal consequences. The framework provides a transparent and transferable approximation for estimating caregiver productivity spillovers when direct caregiver data are unavailable.</p></div>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":"24 6","pages":"1053 - 1068"},"PeriodicalIF":3.1,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149001194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimating the Share of Social Surplus Generated by Pharmaceutical Innovation Accruing to Manufacturers: A Systematic Literature Review 估计药品创新产生的社会剩余份额应归制造商:一个系统的文献综述。
IF 3.1 4区 医学
Applied Health Economics and Health Policy Pub Date : 2026-09-15 DOI: 10.1007/s40258-026-01064-0
Robert J. Nordyke, Tyler D. Wagner, Janine Ross, Sreeranjani Menon, Jonathan D. Campbell
{"title":"Estimating the Share of Social Surplus Generated by Pharmaceutical Innovation Accruing to Manufacturers: A Systematic Literature Review","authors":"Robert J. Nordyke,&nbsp;Tyler D. Wagner,&nbsp;Janine Ross,&nbsp;Sreeranjani Menon,&nbsp;Jonathan D. Campbell","doi":"10.1007/s40258-026-01064-0","DOIUrl":"10.1007/s40258-026-01064-0","url":null,"abstract":"<div><h3>Introduction</h3><p>Pharmaceutical innovation operates within an implicit social contract that seeks to balance incentives for future drug development with equitable access to current therapies. A key metric for evaluating this balance is producer surplus (PS), which represents the share of total social surplus (the sum of consumer surplus [CS] and PS) captured by manufacturers. We explore the determinants and distribution of estimated supply-side surplus share across therapeutic areas, drug classes, and product life cycles.</p><h3>Methods</h3><p>We conducted a systematic literature review of empirical studies on PS in pharmaceuticals. Embase and EconLit databases were searched from database inception to April 2025. Search practices followed Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidance.</p><h3>Results</h3><p>A total of 24 studies were included, representing 68 unique PS estimates. Our analysis reveals wide variation in PS estimates, from 0.3% to 260%, with a median of approximately 15%. The range of estimates is driven primarily by disease-specific factors and methodological inconsistencies. Notably, most studies fail to account for the full spectrum of social benefits or to accurately identify manufacturer revenues, often conflating PS with broader supply chain gains. Only one study met rigorous criteria for both PS and CS definitions.</p><h3>Conclusion</h3><p>The limitations of current studies on PS hinder the utility of PS in value assessment and policymaking. We argue for greater methodological rigor and consistency to improve PS estimation and inform sustainable public policy.</p></div>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":"24 6","pages":"1029 - 1037"},"PeriodicalIF":3.1,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40258-026-01064-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148975426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating Mongolia’s Sugar-Sweetened Beverage Tax: A Cost-Effectiveness Analysis 评价蒙古的含糖饮料税:成本效益分析。
IF 3.1 4区 医学
Applied Health Economics and Health Policy Pub Date : 2026-09-10 DOI: 10.1007/s40258-026-01070-2
Nyamdavaa Byambadorj, Rohan Best, Undram Mandakh, Kompal Sinha
{"title":"Evaluating Mongolia’s Sugar-Sweetened Beverage Tax: A Cost-Effectiveness Analysis","authors":"Nyamdavaa Byambadorj,&nbsp;Rohan Best,&nbsp;Undram Mandakh,&nbsp;Kompal Sinha","doi":"10.1007/s40258-026-01070-2","DOIUrl":"10.1007/s40258-026-01070-2","url":null,"abstract":"<div><h3>Background</h3><p>Mongolia has approved a tax of 20% on sugar-sweetened beverages (SSBs) to take effect in 2027, yet while prior work has assessed potential health impacts, no peer-reviewed study has evaluated its cost-effectiveness.</p><h3>Objective</h3><p>This study evaluates the cost-effectiveness of Mongolia’s planned SSB tax by estimating its effect on health outcomes, healthcare costs, and changes in SSB consumption patterns.</p><h3>Methods</h3><p>Using a Markov cohort model, we project outcomes over 10-year, 20-year and lifetime horizons. The model incorporates changes in the prevalence of overweight and obesity, noncommunicable disease (NCD) incidence, and associated costs, with primary outcomes measured in disability-adjusted life years (DALYs) averted, and quality-adjusted life years (QALYs) gained. To improve precision, disease risk estimates are informed by biomarker data, such as blood sugar and lipid levels, minimizing reliance on self-reported health indicators.</p><h3>Results</h3><p>The ad valorem tax of 20% is projected to reduce consumption of SSBs by 31% through consumer price response alone. Accounting for additional calorie reductions from 20% industry reformulation, the combined effective reduction in SSB-related energy intake reaches approximately 45%. Across the three time horizons, the tax could avert 13, 260 and 2255 premature deaths; yield 2899, 14,362 and 33,613 QALYs; and avert US$6.13 million, US$30.34 million and US$71.02 million, respectively, in healthcare costs. From the healthcare perspective, the tax is cost-effective over 10 years (net cost US$1.77 million; incremental cost-effectiveness ratio (ICER) US$611.99/QALY) and becomes cost-saving within 20 years and over the lifetime horizon.</p><h3>Conclusions</h3><p>These findings support the implementation of the SSB tax as a strategy to reduce Mongolia’s NCD burden and generate long-term fiscal and health benefits.</p></div>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":"24 6","pages":"1069 - 1080"},"PeriodicalIF":3.1,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40258-026-01070-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148928920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
When Does Health Technology Assessment Need Deliberation? Evidence, Algorithms and the Limits of Consultation 卫生技术评估何时需要审议?证据,算法和咨询的限制。
IF 3.1 4区 医学
Applied Health Economics and Health Policy Pub Date : 2026-09-10 DOI: 10.1007/s40258-026-01071-1
Ahmet Küçükuncular, Anthony J. Culyer
{"title":"When Does Health Technology Assessment Need Deliberation? Evidence, Algorithms and the Limits of Consultation","authors":"Ahmet Küçükuncular,&nbsp;Anthony J. Culyer","doi":"10.1007/s40258-026-01071-1","DOIUrl":"10.1007/s40258-026-01071-1","url":null,"abstract":"<div><p>Health technology assessment (HTA) increasingly depends on formal methods such as cost-effectiveness analysis, QALYs, thresholds, structured evidence reviews and decision criteria. These tools are indispensable, but they do not remove the need for judgement. Decisions about health technologies often involve heterogeneous evidence, uncertainty, contested values, institutional constraints, professional responsibilities and consequences for both identifiable patients and anonymous others whose care may be displaced. In this article, we ask when deliberation is likely to be needed in HTA, and what distinguishes it from algorithmic reasoning, consultation and commenting. We argue that deliberation should not be defended simply because it is democratic, inclusive or procedurally attractive. Its value is conditional. Deliberation becomes useful where evidence does not combine itself, where values shape what counts as relevant evidence, and where recommendations must be justified in ways that can withstand disagreement. We distinguish context-free scientific evidence, context-sensitive scientific evidence, and colloquial evidence, and show why their interpretation cannot be reduced to evidence accumulation or modelled calculation. We then identify the circumstances in which deliberation is most likely to add value: (1) when evidence is heterogeneous, incomplete, contested or context dependent, (2) when values, outcomes, equity or fairness are disputed, (3) when implementation is uncertain, and (4) when professional ownership, public credibility or political trust matter. We argue that HTA does not need deliberation everywhere, but where judgement must be exercised, exposed and justified.</p></div>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":"24 6","pages":"943 - 953"},"PeriodicalIF":3.1,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148928951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Scoping Review of the Literature on Child and/or Adolescent Health Microsimulation Models 儿童和/或青少年健康微观模拟模型的文献综述
IF 3.1 4区 医学
Applied Health Economics and Health Policy Pub Date : 2026-09-09 DOI: 10.1007/s40258-026-01066-y
Claire de Oliveira, Yingkun Justin Wen, Michael Endale Mengesha, Filipa Sampaio
{"title":"A Scoping Review of the Literature on Child and/or Adolescent Health Microsimulation Models","authors":"Claire de Oliveira,&nbsp;Yingkun Justin Wen,&nbsp;Michael Endale Mengesha,&nbsp;Filipa Sampaio","doi":"10.1007/s40258-026-01066-y","DOIUrl":"10.1007/s40258-026-01066-y","url":null,"abstract":"<div><h3>Background</h3><p>Microsimulation models can be used for diverse purposes such as forecasting and undertaking economic evaluations. A review of the literature of existing child and/or adolescent microsimulation models has yet to be undertaken. The aim of this scoping review was to retrieve, synthesise and critically appraise the literature of child and/or adolescent health microsimulation models.</p><h3>Methods</h3><p>A scoping review was conducted using PubMed, Embase, CINAHL, PsyclNFO, EconLit and Scopus. Additional searches (snowballing, Google searches, searches of specific journals and websites) were also undertaken to complement database searches. Relevant data on microsimulation models were extracted, and the quality of models was assessed using the Quality Assessment Reporting for Microsimulation Models checklist. Evidence was synthesised by scope of model, type of model and health outcome examined.</p><h3>Results</h3><p>Forty-eight relevant microsimulation models were found. Most (<i>n</i> = 33) were developed specifically for children and/or adolescents, but there were a few (<i>n</i> = 15) broader models that examined these populations. Many microsimulation models were developed for the USA (<i>n</i> = 14); several were focused on select health conditions, such as obesity/overweight, cancer and human immunodeficiency virus (HIV). Just over half (<i>n</i> = 27) of the models found were classified as medium quality models, while the remaining ones were deemed high quality (<i>n</i> = 21). Nonetheless, several models lacked validation and, to a lesser extent, uncertainty analyses and generalisability.</p><h3>Conclusions</h3><p>There are a substantial number of child and/or adolescent health microsimulation models. However, future research should focus on developing models on other prevalent child/adolescent health conditions (e.g. allergies, ADHD) and for low- and middle-income settings.</p></div>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":"24 6","pages":"1039 - 1052"},"PeriodicalIF":3.1,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40258-026-01066-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-Minimisation and Cost-Benefit Analysis of Reusable Menstrual Pads Compared to Disposable Pads in a Low-Resource Nigerian Setting 在资源匮乏的尼日利亚,与一次性卫生巾相比,可重复使用卫生巾的成本最小化和成本效益分析。
IF 3.1 4区 医学
Applied Health Economics and Health Policy Pub Date : 2026-09-09 DOI: 10.1007/s40258-026-01069-9
Amina Suleiman Rajah, Umar Lawal Bello, Ahmed Suberu, Muhammad Kamaluddeen Sani, Muazu Hassan Muazu, Shukurat M. Bello, Japhet Jonah Haruna
{"title":"Cost-Minimisation and Cost-Benefit Analysis of Reusable Menstrual Pads Compared to Disposable Pads in a Low-Resource Nigerian Setting","authors":"Amina Suleiman Rajah,&nbsp;Umar Lawal Bello,&nbsp;Ahmed Suberu,&nbsp;Muhammad Kamaluddeen Sani,&nbsp;Muazu Hassan Muazu,&nbsp;Shukurat M. Bello,&nbsp;Japhet Jonah Haruna","doi":"10.1007/s40258-026-01069-9","DOIUrl":"10.1007/s40258-026-01069-9","url":null,"abstract":"<div><h3>Background</h3><p>Menstrual hygiene management poses significant economic and environmental challenges, with disposable products contributing to period poverty and plastic waste. Robust economic evaluations comparing reusable menstrual pads to disposable alternatives are lacking, particularly in low-income settings.</p><h3>Aim</h3><p>This study assessed the costs, cost-minimisation outcomes, and cost-benefit implications of reusable menstrual pads compared with disposable pads and examined socio-economic factors associated with perceived economic value and willingness to adopt reusable pads.</p><h3>Methods</h3><p>A cross-sectional analytical study was conducted among 426 women and girls in Kano, Nigeria. A cost-minimisation analysis from the user perspective compared the cost per menstrual cycle managed, assuming equivalent menstrual-cycle coverage for reusable and disposable pads. A cost-benefit analysis incorporated monetised environmental externalities related to avoided menstrual waste. Costs were reported in 2025 Nigerian Naira and United States dollars using an exchange rate of ₦1650 = US$1. Sensitivity analyses assessed uncertainty in key cost and waste-management parameters.</p><h3>Results</h3><p>Reusable menstrual pads were more cost-saving compared with disposable pads under the base-case assumptions. Disposable pads cost ₦1425 per cycle, while reusable pads cost ₦413 per cycle. Over 5 years, total undiscounted costs were ₦85,500 for disposable pads and ₦24,780 for reusable pads, yielding net savings of ₦60,720 per user. Including avoided waste-management costs, the net social benefit of switching to reusable pads was ₦63,609 over 5 years. The mean Likert score for the statement that reusable pads are more economical in the long run was 4.26 (SD 0.78), while the mean Likert score for the statement that upfront cost is a major barrier was 4.29 (SD 0.76). Perceived economic value was significantly associated with income (<i>p</i> = 0.003) and education (<i>p</i> &lt; 0.001).</p><h3>Conclusion</h3><p>Reusable menstrual pads may offer substantial cost savings and additional societal benefits through reduced menstrual waste in low-resource contexts. Programmes promoting reusable pads should address the upfront purchase cost through subsidies, financing models, or targeted distribution.</p></div>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":"24 6","pages":"1133 - 1142"},"PeriodicalIF":3.1,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pricing Combination Therapies: A Systematic Review of Value Attribution, Cost-Sharing Mechanisms and Policy Frameworks 定价组合疗法:价值归因、成本分担机制和政策框架的系统回顾。
IF 3.1 4区 医学
Applied Health Economics and Health Policy Pub Date : 2026-09-06 DOI: 10.1007/s40258-026-01065-z
Marta Trapero-Bertran, Carlos Martin-Saborido, Jorge Mestre-Ferrandiz, Nuria Amarilla, Lluís Segú
{"title":"Pricing Combination Therapies: A Systematic Review of Value Attribution, Cost-Sharing Mechanisms and Policy Frameworks","authors":"Marta Trapero-Bertran,&nbsp;Carlos Martin-Saborido,&nbsp;Jorge Mestre-Ferrandiz,&nbsp;Nuria Amarilla,&nbsp;Lluís Segú","doi":"10.1007/s40258-026-01065-z","DOIUrl":"10.1007/s40258-026-01065-z","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;Combination therapies are increasingly central to modern pharmacotherapy, particularly in oncology and other high-burden diseases. However, pharmaceutical pricing and reimbursement systems remain largely designed for single-product-single-indication interventions. When multiple patented medicines are used together, especially when owned by different manufacturers, conventional pricing frameworks may struggle to align prices with the value of the combination while preserving incentives for innovation and timely patient access.&lt;/p&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;To identify, describe, and critically assess the methods, models, and policy frameworks proposed in the literature to establish prices for combination therapies, with particular attention to value attribution mechanisms, cost-sharing arrangements between manufacturers, and budget impact considerations.&lt;/p&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;A systematic literature review was conducted in accordance with PRISMA guidelines and a pre-registered Open Science Framework protocol. Searches were performed in MEDLINE, Scopus, Web of Science, EconLit, CRD databases, and grey literature sources for publications up to July 2025. Eligible studies analysed pricing approaches, economic models, reimbursement mechanisms, or policy frameworks relevant to combination therapies, including more recent multi-indication pricing literature. Given the heterogeneity of the literature, findings were synthesized using a structured narrative and thematic approach.&lt;/p&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;Sixty-nine studies met the inclusion criteria. The literature was dominated by conceptual and policy analyses, with relatively few empirical or implementation-oriented studies. Value attribution emerged as the central methodological challenge in pricing combination therapies. Several complementary approaches were proposed to operationalise value attribution, including adaptations of indication- or pathway-based pricing, manufacturer cost-sharing arrangements, managed entry agreements, and outcome-based reimbursement mechanisms. Empirical evidence suggests that health systems continue to rely primarily on pragmatic and often partial solutions rather than fully specified pricing frameworks. A complementary review of the multi-indication pricing literature indicates that, although the two fields address different pricing problems, they share important methodological and institutional lessons that can inform the development of pricing frameworks for combination therapies.&lt;/p&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;p&gt;The literature provides a growing repertoire of conceptual approaches for pricing combination therapies but limited empirical evidence on implementation. Pricing frameworks should place value attribution at their core while combining complementary policy mechanisms adapted to national pricing and reimbursement systems. Lessons from multi-indication pricing provide a valuable foundation but require additional governance mechanisms to address value at","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":"24 6","pages":"987 - 1004"},"PeriodicalIF":3.1,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40258-026-01065-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书